Table 2.

Stratification analysis for the association between TP53 rs1042522 C>G polymorphism and neuroblastoma susceptibility

Variables	CC	CG/GG	Crude OR	P	Adjusted OR a	P a
	(Cases/Controls)		(95% CI)		(95% CI)
Age, month
≤18	41/88	83/217	0.82 (0.52-1.29)	0.389	0.82 (0.52-1.29)	0.387
>18	94/150	156/356	0.70 (0.51-0.96)	0.028	0.70 (0.51-0.96)	0.027
Gender
Females	50/99	107/242	0.88 (0.58-1.32)	0.524	0.88 (0.58-1.32)	0.537
Males	85/139	132/331	0.65 (0.47-0.91)	0.013	0.66 (0.47-0.92)	0.014
Sites of origin
Adrenal gland	47/238	88/573	0.78 (0.53-1.14)	0.201	0.78 (0.53-1.15)	0.204
Retroperitoneal	29/238	58/573	0.83 (0.52-1.33)	0.440	0.84 (0.52-1.35)	0.468
Mediastinum	46/238	63/573	0.57 (0.38-0.86)	0.007	0.57 (0.38-0.86)	0.007
Others	11/238	24/573	0.91 (0.44-1.88)	0.791	0.91 (0.44-1.89)	0.798
Clinical stages
I+II+4s	59/238	106/573	0.75 (0.53-1.06)	0.104	0.75 (0.53-1.06)	0.105
III+IV	68/238	121/573	0.74 (0.53-1.03)	0.075	0.74 (0.53-1.04)	0.079

^a Adjusted for age and gender, omitting the corresponding stratification factor.